Objective. To assess the role of LN as a risk factor for myocardial infarction (MI), stroke and cardiovascular mortality (CVM) in patients with SLE.
Introduction
SLE is associated with an increased risk of cardiovascular morbidity and cardiovascular mortality (CVM). The risk of cardiovascular events is 1.32.7 times higher in SLE patients than in the general population [14] , and even higher in young SLE patients and in women with SLE [5, 6] . Traditional risk factors like hypertension, dyslipidaemia, sex, age, smoking and obesity as well as SLE-specific and treatment-related factors all contribute to the increased risk of cardiovascular disease [79] . However, the pattern of risk factors causing the excess occurrence of cardiovascular disease in SLE is incompletely characterized.
Patients with SLE develop LN in 1645% of cases during their disease course [1012] . Faurschou et al. [13] examined SLE patients with biopsy-proven LN and found a substantially increased risk of ischaemic heart disease in this subgroup of SLE patients. This observation invites the question of the extent to which LN may explain the increased risk of cardiovascular disease in SLE patients.
To our knowledge, only one previous study of the risk of cardiovascular disease in SLE has distinguished between SLE patients with and without LN [14] . The authors of this population-based case-control study found that LN was associated with a 2.8 times increased risk of acute myocardial infarction (MI) [14] .
The primary aim of the present study was to assess the role of LN as an overall risk factor for MI, stroke and CVM in a nationwide cohort of Danish patients diagnosed with SLE during the 19952011 period.
Methods

Data sources
The study was performed using individual-level data from multiple nationwide administrative data sources. Information from these data sources was linked by means of a unique and permanent personal identification number, which is assigned to all Danish citizens at the time of their birth or immigration [15] . We obtained data on morbidity by linkage to the Danish National Patient Register. The Danish National Patient Register is an administrative register that contains information on all inpatient (from 1977) and outpatient (from 1995) hospital contacts in Denmark. Diagnoses are coded according to the International Classification of Diseases (ICD) with use of the eighth revision (ICD-8) until 1994 and the 10th revision (ICD-10) thereafter. Each individual contact is registered with one primary diagnosis and, if appropriate, one or more supplementary diagnoses [16] .
Information on CVM was obtained from the Danish Register of Causes of Death. Causes of death among all citizens in Denmark have been classified according to the ICD-8 during 197894 and the ICD-10 since 1994 [17] . Data on income were obtained from Statistics Denmark, which is the central authority on statistics in Denmark [18] . All data were made available by Statistics Denmark in anonymized form.
Study cohorts
We identified patients with incident SLE by use of a previously validated algorithm with positive predictive values of 86% and 90% for the case definitions of SLE without LN and SLE with LN, respectively [12] . In brief, we identified all persons who, firstly, were registered in the Danish National Patient Register with a first-time SLE diagnosis during the 19952011 period (ICD-10 codes DM321, DM328, DM329), secondly, were aged 518 years at their date of diagnosis, and finally, had at least 1 year of out-patient follow-up under this diagnosis or consecutive in-patient admissions coded with an SLE diagnosis with <3-month intervals during the first year of follow-up [12] .
Patients with incident LN within the SLE cohort were identified as those who had one or more hospital contacts for nephritis or complication thereof (DN00-DN06, DN082,  DN085, DN162, DN164, DN168, DN18, DN19, DN26 or M32.1B) concomitantly with or after the first hospital contact for SLE [12] .
For each patient with SLE, we identified five randomly selected, age-and sex-matched population controls from the general population of Denmark. The study index date for SLE patients was defined as the date they fulfilled the selection criteria. The population controls were assigned the index date of their respective cases.
Outcome measures
We identified events of MI by hospital contacts registered with the ICD-8 code 410 or the ICD-10 code I21. Stroke events were identified by hospital contacts with the ICD-8 codes 431, 432, 433 and 434 or the ICD-10 codes I61, I62.9, I63 and I64. Registrations of MI and stroke have previously been validated in the Danish National Patient Register. The positive predictive value of an MI registration was found to be at least 90%, and the positive predictive value of stroke registrations was 80.586% [1921] . CVM was identified by the ICD-10 codes I00I99 (excluding I33, I38 and I39) in the Danish Registry of Causes of Death.
A Charlson Comorbidity Index score was calculated at the index date based on relevant diagnostic codes [22, 23] . The Charlson Comorbidity Index score is a validated, weighted co-morbidity score based on the incidence of 19 conditions of comorbidity [22, 24] . In the present study, SLE and renal diseases were excluded from the Charlson Comorbidity Index to ensure comparability between SLE patients and population controls. Charlson Comorbidity Index scores were categorized as 0, 1 or 52. Income was categorized as low, middle or high and was calculated based on tertiles according to personal income during the past 5 years prior to the index date.
Statistical analysis
We followed the cohort participants from the index date to the date of the cardiovascular event of interest, emigration, death, loss to follow-up or until 31 December 2011, whichever came first. As LN could present at the SLE diagnosis or at any time thereafter, we considered LN a time-dependent exposure. Thus, SLE patients who developed LN contributed with time at risk in the group of SLE patients without LN until the date of LN. For each outcome (MI, stroke and CVM) we calculated overall incidence rates and incidence rates stratified by age, sex and follow-up for SLE patients with and without LN and their matched population controls. To control for the differences in factors associated with the outcome among SLE patients with and without LN, hazard ratios (HRs) were estimated by semiparametric proportional hazard models including all participants with appropriate stratification within the model and LN included as a time-dependent covariate. The HRs associated with LN as well as the HRs associated with SLE patients with and without LN compared with their respective population controls were reported. In the models examining the effect of follow-up, time was divided into two periods: the first 2 years and from 2 years and onwards (calculated from SLE diagnosis and from onset LN, if present). We calculated sex-and age-adjusted HRs as well as HRs adjusted for sex, age, Charlson Comorbidity Index score and income (fully adjusted HRs). For MI and stroke, we excluded participants from the analyses if they had the outcome of interest prior to the index date. For CVM, the fully adjusted HRs also included adjustment for events of MI and/or stroke prior to the index date. Throughout the Results section, we report solely the fully adjusted HRs. The proportional hazards assumption was assessed both graphically and by formal testing (based on Schoenfeld residuals) and was satisfied unless otherwise noted. A twotailed P < 0.05 was considered significant and 95% CIs were used.
We used SAS version 9.2 (SAS Institute, Cary, NC, USA) for data management and Stata version 14.0 (StataCorp, College Station, TX, USA) for statistical analysis.
Ethics
This study was approved by The Danish Data Protection Agency (2007-58-0015). In order to comply with regulations on anonymity of participants, infrequent events were reported as '<3' where appropriate. Specific ethical approval was not required as this was a register-based study.
Results
Cohort characteristics
We identified a total of 1644 incident SLE patients of whom 233 developed LN. The characteristics of the SLE patients according to whether or not they developed LN and their matched population controls are presented in Table 1 . SLE patients with LN had a lower median age at the SLE index date than SLE patients without LN. We observed only minor differences in Charlson Comorbidity Index scores and income between the SLE patients and their population controls (Table 1) . Overall median followup time was 7.8 years (range 017; interquartile range: 3.312.7). LN was diagnosed concomitantly with SLE in 135 (58%) of the patients. In the remaining 98 (42%) patients with LN, the LN diagnosis was made after the first diagnosis of SLE. The median time from SLE to LN diagnosis for those patients was 3.7 years (interquartile range: 1.57.3).
MI
The incidence rate for MI in all patients with SLE and all population controls was 3.4 and 1.4/1000 person-years, respectively. This corresponded to a HR of 3.0 (95% CI: 2.0, 4.5) among all SLE patients compared with their population controls. Table 2 shows the number of events, incidence rates, the HRs for MI in SLE patients without and with LN, and the HRs for LN. The HR for MI was 2.2 (95% CI: 1.4, 3.4) in SLE patients without LN and 18.3 (95% CI: 5.1, 65) in SLE patients with LN when compared with their population controls. Consequently, we found that LN was associated with an 8-fold increase in the risk of MI (HR = 8.5, 95% CI: 2.2, 33; P = 0.002). The HRs were considerably higher among SLE patients with LN than among SLE patients without LN across sex and age groups, but not significantly for men and patients >55 years of age.
In SLE patients without LN, the HR for MI was increased after >2 years of follow-up, but not during the first 2 years. In contrast, the HRs for MI in SLE patients with LN were For SLE patients without LN, the HR was 2.1 (95% CI: 1.5, 2.9); for SLE patients with LN, it was roughly twice as high (HR: 4.1, 95% CI: 1.9, 8.7). Nevertheless, we found no significant association between LN and the risk of stroke (HR: 1.9, 95% CI: 0.9, 4.4; P = 0.115) ( Table 3) . In both SLE patients with and without LN, the risk of stroke was only increased among women. Of note, the proportional hazards assumption for the overall risk of stroke in women with LN was violated, reflecting the marked difference in risk of stroke in the early and late follow-up periods (resolved by the presented stratification of 02 years and >2 years of follow-up).
In SLE patients without LN, the HRs of stroke were highest during early follow-up compared with late followup. In contrast, the HRs of stroke did not decrease beyond the second year of follow-up in SLE patients with LN (Table 3) .
CVM
The respective incidence rates for CVM in all SLE patients and all population controls were 4.4 and 2.3/1000 personyears. The corresponding overall HR was 2.0 (95% CI: 1.4, 2.9) among all SLE patients compared with their population controls. Table 4 presents the number of deaths, incidence rates, the HRs for CVM among SLE patients with and without LN, and the HRs for LN. The HR for CVM in SLE patients without LN was 1.6 (95% CI: 1.1, 2.5) and in SLE patients with LN it was 7.8 (95% CI: 3.0, 20) when compared with the matched population controls. Accordingly, LN was associated with a >4-fold increased risk of CVM (HR: 4.9, 95% CI: 1.8, 13.7; P = 0.002). Much higher HRs were observed for patients with LN than for patients without LN across sex and age groups.
During the first 2 years of follow-up, SLE patients with LN had an 9 times higher relative risk of CVM than SLE patients without LN (HR = 9.0, 95% CI: 2.6, 31 vs HR = 1.1, 95% CI: 0.5, 2.4). During late follow-up, the risk of CVM among SLE patients without LN increased and became significantly different from that of the control group (HR: 1.8, 95% CI: 1.2, 2.8). For SLE patients with LN, the HR for CVM during late follow-up was comparable to that observed during early follow-up.
Discussion
In this nationwide, population-based cohort study, we observed an excess occurrence of MI, stroke and CVM in SLE patients with and without LN. For MI and CVM, we found significantly higher overall risk estimates in SLE In a population-based case-control study, Wells et al. [14] concluded that LN was associated with a 2.8-fold increased risk of acute MI among patients with SLE. We found a nearly nine times higher risk of MI in patients with LN than in SLE patients without LN. However, the observations reported by Wells et al. may not be directly comparable with ours due to different methodological approaches. Thus, in the study by Wells et al. [14] , the cases consisted of SLE patients hospitalized with acute MI, and the controls were SLE patients hospitalized with asthma or chronic obstructive pulmonary disease, whereas in the present study we compared SLE patients with population controls with respect to the risk of cardiovascular events. Moreover, the two studies differ in terms of SLE case definition and the ethnicity of the study populations.
A recent Danish nationwide cohort study investigating cardiovascular risk in SLE and cutaneous lupus reported a HR of 2.05 (95% CI: 1.83, 2.30) for the composite end point of stroke, acute MI and CVM among such patients compared with the general population [4] . Hesselvig et al. [4] used the Danish National Patient Register as the data source like we did. However, we observed slightly higher HRs for MI, stroke and CVM when investigating the endpoints separately for all SLE patients (with and without LN) compared with all population controls. This difference in the results may be explained by the fact that Hesselvig et al. [4] used a non-validated case definition and thereby included more misclassified SLE cases than we did.
A number of strengths and limitations of the present study should be mentioned; the strengths include the use of nationwide register-derived data, the high number of participants, the long duration of follow-up and the validated case definitions [12] .
A limitation of the case definition is that the Danish National Patient Register lacks information on clinical characteristics. The lack of detailed clinical and biochemical information prevented us from exploring the cardiovascular risk associated with disease-specific and traditional cardiovascular risk factors such as aPL positivity, cholesterol levels, blood pressure levels and smoking status. To some extent, these risk factors were included in the analysis as we determined the participants' baseline comorbidity; however, we are unable to state whether inclusion of these clinical variables would have changed the risk estimates. Furthermore, the lack of data on medications in the registers used prevented us from investigating the impact of medications on the increased risk of cardiovascular events. Accordingly, we were unable to determine to what degree the increased risk of cardiovascular events in the subgroup of SLE patients with LN was due to the nephritis itself, to changes in traditional cardiovascular risk factors due to nephritis and/or medications used to treat nephritis. Finally, the small numbers in some of the subgroups (e.g. men) may cause less statistical power. This should be kept in mind when interpreting the results in these subgroups.
In summary, our study demonstrates a considerably higher risk of MI and CVM in SLE patients with LN than in SLE patients without LN. In contrast, we do not find that the enhanced risk of stroke in SLE is substantially influenced by the presence of LN. Our findings indicate that systematic screening for cardiovascular risk factors should be considered in all patients with SLE, and that the subgroup of SLE patients with LN should be acknowledged as having a particularly high risk of cardiovascular events during both early and later phases of their disease course.
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